Skip to content
Today
Sections

Invest Reports disagree6 publishers 3 min read Published Updated

Moderna doubles on a Phase 3 win whose effect size has not been published yet

Intismeran autogene plus Keytruda beat Keytruda alone in resected melanoma. The market added roughly $35bn to Moderna on a result the companies described only in adjectives.

The Investor · Invest desk

Send a correction

What happened

  • Moderna and Merck said Wednesday their personalized mRNA cancer vaccine, intismeran autogene, built from a sample of a patient's own tumour, met its main goals in a Phase 3 trial targeting melanoma, the first time a therapy of its kind succeeded at that stage of testing.
  • The Phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda met its recurrence-free survival and distant-metastasis-free survival endpoints in patients whose stage IIB-IV melanoma had been surgically removed.
  • Moderna shares surged about 131% on Wednesday, more than doubling to near $148 after touching $163 intraday, a record one-day jump.
  • A close near $148 after a 131% gain implies a prior closing price of about $64.
  • SCMP reported Moderna shares up more than 90 per cent to around US$120 a share in early New York trading, with Merck's stock up 10 per cent.

Why it matters

Moderna and Merck said on Wednesday that intismeran autogene, an mRNA vaccine built from each patient's own tumour mutations, met both primary endpoints in the Phase 3 INTerpath-001 trial in patients whose melanoma had been surgically removed [1][2]. Moderna's stock rose about 131% to near $148, a record one-day move, repricing a company that had been leaning on a collapsed COVID franchise on the strength of a result whose actual effect size has not been released [19][12][5].

The trial enrolled 1,137 patients with high-risk stage IIB to IV melanoma, all resected before enrolment [6]. One arm received Keytruda plus the personalised vaccine up to nine times over roughly a year, the other Keytruda alone, which is the current standard of care in the adjuvant setting [7][4]. The combination beat it on recurrence-free and distant-metastasis-free survival at an interim analysis, with no new safety concerns identified [2][3][7]. The companies characterised the improvement only as "statistically significant and clinically meaningful" and said full data will go to a medical conference and to regulators [5]. Overall survival and other secondary endpoints have not been reported [11].

So investors are pricing the Phase 2 numbers Merck cited in its own release: a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death against Keytruda alone [9], from five-year follow-up published in January [10]. Danish Nagda, an otolaryngologist and chief executive of Rezilient Health, told Fortune that five-year recurrence-free survival in stage 3 and 4 melanoma currently runs around 20% to 35% and that the combination "potentially doubles it" [15]. That is one clinician's read, not trial data.

The asymmetry between the two partners is the part worth sitting with. Merck is valued at roughly $371bn against Moderna's roughly $62bn [23], about 17% of its partner [24]. Merck's shares rose about 10% in early trading [20], which on that base is roughly $34bn of market value [26] - approximately the entire gain Moderna booked on the day, since a 131% rise implies a pre-announcement value near $27bn [22][25]. For Merck this is an adjuvant extension of an existing franchise. For Moderna it is the first commercial argument for the platform that is not COVID.

Part of the move is mechanical. Short interest sat at 13.5% of free float and shorts took about $4.8bn in mark-to-market losses [13]. ORTEX co-founder Peter Hillerberg said each shorted share was "now down almost $100, that is exactly the kind of pressure that can trigger a squeeze" [14]. Early quotes also diverged: SCMP reported Moderna up more than 90% to about $120 [20], while a Reuters-sourced premarket quote carried by Seoul Economic Daily put the stock at $37.15, up 59% [21], a level that does not reconcile with the day's other prints.

The operational question the price is not yet answering is manufacture. Each dose requires sequencing an individual tumour and mapping its mutations, and the therapy is dosed up to nine times per patient [8][7]. That is a per-patient production line, not vials. The addressable population is real - the National Cancer Institute counted more than 1.5 million melanoma patients in the United States in 2023 [18] - but Merck Research Laboratories president Dean Y. Li framed the ambition specifically as resected stage IIB-IV disease [17].

Watch three things: the effect size when the full dataset is presented and taken to regulators [5], overall survival [11], and whether the squeeze-driven portion of the rally unwinds. Nagda also argued Moderna is now an acquisition target and still undervalued [16]; that view is his alone.

Information, not investment advice. This story is general information about companies and markets, drawn from cited reporting. It is not a recommendation to buy, sell or hold any security; check the cited sources before acting.

Clarity's read

What the record supports and how the coverage leans. The claims behind it follow.

Reality

Evidence45
Adoption5
Hype gap+55
Incentives70
Confidence60

Perspective Coverage

6 publishers
Builder
Builder 29%
Operator
Operator 25%
Investor
Investor 46%
Why these scores

Claim ledger

Ranked by verification strength, evidence, and original report placement.

  1. [1]

    Moderna and Merck said Wednesday their personalized mRNA cancer vaccine, intismeran autogene, built from a sample of a patient's own tumour, met its main goals in a Phase 3 trial targeting melanoma, the first time a therapy of its kind succeeded at that stage of testing.

    Reported SupportedView cited source
  2. [2]

    The Phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda met its recurrence-free survival and distant-metastasis-free survival endpoints in patients whose stage IIB-IV melanoma had been surgically removed.

    Reported SupportedView cited source
  3. [3]

    The trial is still underway but met its primary goals in an interim analysis.

    Reported SupportedView cited source
  4. [4]

    Keytruda alone is the current standard of care in the adjuvant setting, and the Moderna-Merck combination beat it on both endpoints.

    Reported SupportedView cited source
  5. [5]

    The companies have not released the exact numbers behind the improvement, saying only that results were "statistically significant and clinically meaningful", and plan to share full data at an upcoming medical conference and bring the results to regulators.

    Reported SupportedView cited source
  6. [6]

    The trial included 1,137 patients with high-risk stage 2B to stage 4 melanoma who had undergone surgery to remove their tumours before enrolling.

    Reported SupportedView cited source
  7. [7]

    Participants were randomly assigned so that one group received Keytruda plus the personalized vaccine up to nine times over about a year and the other received Keytruda alone; Moderna and Merck said no new safety concerns were identified.

    Reported SupportedView cited source
  8. [8]

    Intismeran autogene, also called V940 or mRNA-4157, is not mass-produced: doctors sequence a patient's tumour, map its unique mutations, and the mRNA teaches the body to manufacture neoantigens the immune system learns to attack.

    Reported SupportedView cited source
  9. [9]

    Earlier data from the same drug combination showed a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death compared with Keytruda alone; Merck referenced those figures in Wednesday's release.

    Reported SupportedView cited source
  10. [10]

    Five-year follow-up results from the earlier mid-stage trial, released this past January, showed patients receiving Keytruda plus the personalized vaccine had a 49% lower risk of cancer recurrence or death than those given Keytruda alone.

    Reported SupportedView cited source
  11. [11]

    The trial will continue to evaluate overall survival and other secondary endpoints not yet reported.

    Reported SupportedView cited source
  12. [12]

    Moderna has leaned on a collapsed COVID franchise and carried one of the heaviest short bets among large caps, making the readout a make-or-break moment.

    Reported SupportedView cited source
  13. [13]

    Traders shorting Moderna faced about $4.8bn in mark-to-market losses as the stock doubled; short interest sat at 13.5% of free float.

    Reported SupportedView cited source
  14. [14]

    ORTEX co-founder Peter Hillerberg said in a statement: "With each shorted share now down almost $100, that is exactly the kind of pressure that can trigger a squeeze."

    Reported SupportedView cited source
  15. [15]

    Dr Danish Nagda, an otolaryngologist who has treated head and neck melanoma patients and founder and CEO of Rezilient Health, told Fortune that five-year recurrence-free survival for advanced stage three or four melanoma runs around 20 to 35% today, and said the combination "potentially doubles it".

    Reported SupportedView cited source
  16. [16]

    Nagda told Fortune the result "makes Moderna a great acquisition target" and that "Moderna is still incredibly undervalued", with the stock move underestimating the value of the platform.

    Reported SupportedView cited source
  17. [17]

    Dr Dean Y. Li, president of Merck Research Laboratories, said individualized neoantigen therapies have the potential to redefine how patients with completely resected stage IIB-IV melanoma are treated, and that adjuvant therapy after surgery aims to increase the possibility of cure.

    Reported SupportedView cited source
  18. [18]

    According to the U.S. National Cancer Institute, the number of melanoma patients in the United States surpassed 1.5 million in 2023.

    Reported SupportedView cited source
  19. [19]

    Moderna shares surged about 131% on Wednesday, more than doubling to near $148 after touching $163 intraday, a record one-day jump.

    Reported ContestedView cited source
  20. [20]

    SCMP reported Moderna shares up more than 90 per cent to around US$120 a share in early New York trading, with Merck's stock up 10 per cent.

    Reported ContestedView cited source
  21. [21]

    Seoul Economic Daily, citing Reuters, reported Moderna trading at $37.15, up 59.01% from the previous session, at 7:18 a.m. Eastern in premarket trading, with Merck up 6.53% to $143.99.

    Reported ContestedView cited source
  22. [22]

    A close near $148 after a 131% gain implies a prior closing price of about $64.

    Derived Contested
  23. [23]

    Merck is currently valued at roughly $371 billion and Moderna at around $62 billion.

    Reported ContestedView cited source
  24. [24]

    Moderna's roughly $62bn valuation is about 17% of Merck's roughly $371bn.

    Derived Contested
  25. [25]

    A 131% gain to a roughly $62bn market value implies a pre-announcement value near $27bn and a one-day gain of about $35bn.

    Derived Contested
  26. [26]

    A 10% rise on a roughly $371bn valuation corresponds to about $34bn of added market value.

    Derived Contested

Sources

6 independent publishers whose own reporting we read for this story.

  1. decrypt.co

    1 article · August 19, 2026

    Moderna Stock Doubles on Cancer Breakthrough: Here’s What It Means
  2. en.sedaily.com

    1 article · August 19, 2026

    Moderna Shares Soar 59% on Positive Late-Stage Cancer Vaccine Data
  3. fortune.com

    1 article · August 19, 2026

    Moderna’s and Merck’s personalized mRNA vaccine shows real promise against deadly skin cancer melanoma in late stage trial and sends stocks soaring
  4. scmp.com

    1 article · August 19, 2026

    Merck, Moderna claim encouraging melanoma vaccine trial results
  5. semafor.com

    1 article · August 19, 2026

    Moderna's skin cancer vaccine shows promise in trial
  6. thedailyupside.com

    1 article · August 19, 2026

    Moderna Soars as Vaccine-Drug Combo Slows Recurrence of Melanoma

Topics and entities

Topics

Entities